Pharmaceutical Industry: Accelerated Digital and Intelligent Transformation, with Global Expansion of Innovative Drugs Emerging as a New Trend

In 2025, driven by both policy dividends and technological revolutions, China's pharmaceutical industry is accelerating towards a stage of high-quality development. With the in-depth advancement of the "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025–2030)," cutting-edge technologies such as AI-driven drug discovery, gene editing, and cell therapy have emerged as the core engines of industrial upgrading, bringing about profound changes in the industry ecosystem.

AI Technology Reshapes R&D Paradigms, Optimizing Both Efficiency and Costs
AI technology is permeating the entire pharmaceutical industry chain. XtalPi's self-developed AI drug discovery platform has shortened the lead compound screening cycle from the traditional 18 months to just 6 months, reducing R&D costs by 70%. Its anti-allergy drug, XCL-001, has entered Phase III clinical trials, becoming the world's first late-stage small-molecule drug predominantly discovered by AI. WuXi AppTec's AI-assisted platform has successfully predicted the active ingredients of three classic traditional Chinese medicine formulas, enhancing R&D efficiency by 50% and shortening the validation cycle by 60%. Additionally, Moderna's collaboration with Merck on an mRNA cancer vaccine has optimized antigen design through AI, increasing efficiency by 30% and advancing to Phase III trials.

Accelerated Global Expansion of Innovative Drugs, with Deepened Internationalization Strategies
Chinese pharmaceutical companies are accelerating their global market layout. Hengrui Medicine's PD-1 monoclonal antibody, camrelizumab, has secured overseas licensing deals worth 1.2billion,withinternationalrevenueaccountingforover255 billion in 2024.

Deepened Digital and Intelligent Transformation, Upgrading the Entire Industry Chain
The implementation plan jointly issued by seven ministries and commissions, including the Ministry of Industry and Information Technology, aims to break through 100 key digital and intelligent technologies and establish 50 benchmark enterprises by 2027. Yunnan Baiyao's intelligent factory has tripled its packaging efficiency through a robotic sorting system, increasing the first-pass yield from 92% to 99.2%. Tofflon and Truking Technology have broken through technological barriers in bioreactors, with the domestic equipment market share expected to exceed 40% in 2025. Blockchain traceability platforms have connected over 100,000 enterprises, with scanning queries exceeding 1 billion times and a counterfeit drug identification rate approaching 100%.

Dual Drivers of Policy and Capital Accelerate Industry Consolidation
The State Drug Administration's "Implementation Plan for Full-Chain Support of Innovative Drug Development" has been implemented, with innovative drugs mentioned for the first time in the State Council's government work report. The number of IND applications has reached 628, a year-on-year increase of 32%. VC financing in 2025 is expected to reach 27.7 billion, with the IPO market showing signs of recovery. M&A activities focus on medium-sized transactions, such as Vertex's4.9 billion acquisition of Alpine Immune Sciences to strengthen its nephrology pipeline. Over the next decade, China's pharmaceutical industry is set to transition from a "follower" to a "parallel runner" and eventually a "leader," with gene editing, AI-driven drug discovery, and cell therapy becoming core growth points.